Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-mannosylceramide
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
Alpha-mannosylceramide (α-ManCer) is a synthetic glycolipid and monoglycosyl ceramide characterized by an alpha-linked mannose sugar moiety. It functions as a potent agonist for the Vα19-Jα26 invariant natural killer T (NKT) cell repertoire, a unique subset of T cells that recognize glycolipid antigens presented by the non-classical MHC-like molecule CD1d. While structurally related to the prototypical NKT agonist alpha-galactosylceramide (α-GalCer), α-ManCer has shown distinct biological activities in preclinical models. For instance, research has indicated that α-ManCer does not induce significant anti-tumor immunity in certain murine models of colon carcinoma and melanoma, unlike its beta-linked counterpart (β-ManCer). It is primarily utilized as a research tool in immunology to investigate NKT cell activation and potential immunotherapeutic strategies.
- Other names
- alpha-mannosylceramideα-mannosylceramide
02
Targets
CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)Invariant Vα19-Jα26 NKT T-cell receptor
Beyond the preview
Go deeper on alpha-mannosylceramide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-mannosylceramide.